Objective: The aim of this study is to assess whether the levels and progression rates of carotid intima-media thickness (IMT) and adventitial diameter (AD) vary by menopausal stage.
T he incidence rate for cardiovascular diseases (CVDs), the leading cause of death in women, increases after the age of 50 years, 1 when most women are transitioning to menopause. This suggests a possible link between the men-opausal transition and the development of CVDs. Whether menopause or age-related changes are associated with the increased incidence rate for CVDs remains an active area of research. Studies show that earlier age at menopause, 2 premature menopause, and surgically induced menopause 3, 4 are significant risk factors for CVDs, suggesting an effect of menopause on CVD risk independent of age.
Menopause is accompanied by several physiological changes that potentially contribute to the increased risk of CVDs, including cessation of ovarian estrogen secretion, changes in body fat distribution, 5 and adverse changes in lipid profile. 6 Furthermore, menopause has been linked to metabolic syndrome, insulin resistance, 7 and changes in plasma adiponectin levels. 8 For a better understanding of the potential role of menopause in the development of CVDs, it is important to evaluate whether the menopausal transition is associated with the progression of subclinical measures of CVDs independent of age.
Previous studies that examined the relationship between the menopausal transition and subclinical CVDs have been mainly cross-sectional and focused on intima-media thickness (IMT) and arterial distensibility. 9<11 One such study showed that women at 5 to 8 years after menopause have larger IMT measures than premenopausal women. 9 Furthermore, premenopausal cardiovascular risk factors, 9, 10 as well as the change in pulse pressure between premenopause and the first year postmenopause, 10 have been reported to be independently associated with IMT measured after menopause. In addition, compared with premenopausal women, postmenopausal women have significantly lower arterial distension. 11 Previous findings from the Study of Women's Health Across the Nation (SWAN) have shown that late perimenopause was associated with a larger common carotid adventitial diameter (AD) compared with premenopause/early perimenopause on multivariable analysis. 12 However, this analysis was limited by its cross-sectional design and lack of data on the progression rates of subclinical CVDs in the different stages of the menopausal transition.
The purposes of the present study were to (1) estimate and compare the progression rates of carotid IMT and AD across the four stages of the menopausal transition (premenopausal, early perimenopausal, late perimenopausal, and postmenopausal stages) and (2) to determine the independent effects of menopause status on IMT and AD levels in women transitioning through menopause.
METHODS

Study participants
SWAN is an ongoing, longitudinal, multiethnic study of biological, physical, psychological, and social changes during the menopausal transition. The study design has been previously reported. 13 In brief, between 1996 and 1997, 3,302 participants aged 42 to 52 years were recruited from seven designated sites (Boston, MA; Detroit, MI; Oakland, CA; Los Angeles, CA; Pittsburgh, PA; Chicago, IL; and Newark, NJ). The eligibility criteria for SWAN were as follows: (1) has an intact uterus and at least one ovary; (2) is not pregnant or breast-feeding; (3) has had at least one menstrual period within the past 3 months; and (4) has not undergone hormone therapy within the past 3 months.
Participants in the current study were part of an ancillary study to SWAN at the Pittsburgh site. Enrollment began between the baseline and the third annual visit of SWAN (N = 257). Participants were deemed eligible if they were not pregnant. Each participant underwent up to five carotid scans (815 total scans) for a maximum of 9 years of follow-up (median, 3.7 y).
For the current analysis, data were censored at the time the participant underwent hysterectomy (n = 27 observations), developed stroke and/or angina (n = 3 observations), or started hormone therapy (n = 179 observations). The final analysis included 249 participants with a total of 606 scans.
Research protocols were approved by the institutional review board at each site, and all the participants provided a written informed consent form before enrollment.
Study measures Ultrasound measures
The IMT and AD of the right and left carotid arteries were assessed by B-mode ultrasound using a Toshiba SSA-270A scanner (Toshiba American Medical Systems, Tustin, CA). For IMT, B-mode images were obtained from eight locations (four each from the left and right carotid arteries): the near and far walls of the distal common carotid artery (1 cm proximal to the carotid bulb), the far walls of the carotid bulb, and the internal carotid artery (from the flow divider to 1 cm distal to this point). IMT measures were obtained by electronically tracing the lumen-intima interface and the media-adventitia interface across a 1-cm segment; one measurement was generated for each pixel over the area, for approximately 140 measures for each segment. For analyses, the mean value of the average readings at all eight locations was used.
For AD, the distance from the adventitia-media interface on the near wall to the media-adventitia interface on the far wall at end-diastole was measured for both the right common carotid artery and the left common carotid artery. For analyses, the average value of the readings at both sides was used. All readings were conducted at the University of Pittsburgh Ultrasound Research Laboratory. Readers were centrally trained with a standardized protocol and recertified annually against the same set of scans to guard against reader drift. Readers were blinded to the participants' clinical information. Replicate readings were performed on 20 scans to determine the inter-reader reproducibility of subclinical measures, with intraclass correlations of 0.98 and 0.99 for IMT and AD, respectively.
Blood assays
A fasting blood specimen was obtained either during the early follicular phase of the menstrual cycle (days 2-5) for menstruating participants or randomly within the 90-day period of recruitment for perimenopausal and postmenopausal women. Lipids, glucose, insulin, and C-reactive protein (CRP) were assayed at the Medical Research Laboratories (Lexington, KY) certified by the National Heart, Lung, and Blood Institute, Centers for Disease Control and Prevention Part III program. 14 Total cholesterol and triglyceride levels were analyzed with enzymatic methods on a Hitachi 747 analyzer (Boehringer-Mannheim Diagnostics, Indianapolis, IN), and high-density lipoprotein cholesterol was isolated using heparin manganese. Low-density lipoprotein cholesterol (LDL-c) was calculated using the Friedewald equation. 15 Serum insulin was measured by radioimmunoassay (DPC Coat-a-Count) and monitored as part of a monthly quality assurance program. Glucose was measured with a hexokinase-coupled reaction (Boehringer-Mannheim Diagnostics). The homeostasis model assessment (HOMA) index was calculated from fasting insulin and glucose as (insulin (mU/L) Â glucose (mmol/L)/22.5. 16 CRP was quantified using an ultrasensitive rate immunonephelometric method (high-sensitivity CRP on BN 100; Dade-Behring, Marburg, Germany). The CRP assay within-run coefficient of variation was 3.3%. The between-day imprecision was 4.0% at a concentration of 58.9 mg/L and 6.8% at a concentration of 10.2 mg/L. 17 
Physical measures
Weight and height were measured annually. Body mass index (BMI) was calculated as weight/height 2 . Blood pressure was averaged after two sequential measures in the right arm, with the participant seated after at least 5 minutes of rest.
Physical activity was assessed via Modified Baecke Scores of Habitual Physical Activity, with higher scores indicating more physical activity. 18 
Demographic, socioeconomic, comorbidity, and smoking variables
Race/ethnicity was self-reported. Age and current smoking status were derived from interviews administered during each annual visit. Hypertension and use of CVD medications (any reported use of medication for heart condition, an anticoagulant, or blood-pressure-lowering medication in the past year) were combined into a single comorbidity variable.
Menopause status
Menopause status was determined annually based on reports about the frequency and regularity of menstrual bleeding and use of hormone therapy, 19 as follows: (1) premenopause: monthly bleeding with no perceived change in cycle interval in the past year; (2) early perimenopause: menses in the last 3 months with some change in regularity during the prior 12 months; (3) late perimenopause: three consecutive months of amenorrhea; (4) postmenopause: 12 consecutive months of amenorrhea; (5) surgical menopause: menopause induced by hysterectomy with/without oophorectomy; and (6) unknown: use of hormone therapy before documentation of the final menstrual period.
Statistical analysis
AD values were normally distributed, whereas IMT values were slightly skewed. Therefore, IMT was examined with and without log transformation. Because results were similar, results from models using the original values of IMT were presented for ease of interpretation. Triglycerides, glucose, insulin, HOMA index, and CRP were highly skewed and logtransformed for analyses.
The overall rates of change in IMT and AD during the study were estimated using linear mixed-effect models to account for within-subject correlation and unequal intervals between measurements. 20 To estimate the rates of change during each stage of the menopausal transition, we modeled repeated measures of each outcome (IMT and AD) as a function of four separate time variables: one for the cumulative amount of time spent in each of the four menopausal stages since baseline. The algorithm used to calculate the cumulative time spent in each menopausal stage was successfully applied in a previous analysis from SWAN. 21 We modified the algorithm to reflect the cumulative time spent in each stage since the baseline carotid scan (see Supplemental Digital Content 1, http://links.lww.com/MENO/A38). The A coefficients for these four time variables provided estimates of the annual change in IMT/AD for each menopausal stage. These models were adjusted for age at baseline and race. Contrasts were used to compare the rates of change in IMT and AD across the menopausal transition stages (four time variables).
Maximal likelihood linear mixed-effect models were used and both unadjusted and adjusted models were fitted to determine the risk factors for greater IMT and AD. All included variables, except for age and race, were time-dependent. Variables were included in the models based on P values from univariate analysis (P G 0.05), starting with those having the lowest P values. Variables with P Q 0.1 in the final models were dropped. For variables that were highly correlated (eg, BMI and waist circumference), models were tested with each of these variables separately, and the model that showed better fit was selected.
The effect of status (modeled as concurrent menopause status; time-dependent) was assessed before and after adjusting for significant risk factors identified through the current analyses to test the independent effect of menopause status on IMT and AD levels. The regression coefficients for menopause status categories indicate the differences in IMT/AD levels compared with premenopause status (reference group). Risk factors were modeled using two different approaches: (1) as concurrent measures (time-dependent) and (2) as baseline (to assess cross-sectional effect) and change since baseline (to assess longitudinal effect). Changes since baseline were not significantly related to IMT or AD levels. Therefore, only results using the first approach of modeling risk factors were presented. Models with smaller Akaike information criterion were considered a better fit. All continuous variables were centered to their means (except for time, which was computed as time since baseline) to obtain a meaningful intercept.
Residual analysis and diagnostic plots were conducted to verify model assumptions. Analyses were performed with SAS, version 9.2 (SAS Institute, Cary, NC). All tests were two-sided, with an > of 0.05. Table 1 shows the main characteristics of the study population at baseline scan. Table 2 presents the statistics of subclinical measures and traditional cardiovascular risk factors at baseline.
RESULTS
The unadjusted overall rate of change in IMT was 0.007 mm/year. When the rate of change was examined at each menopausal stage after adjustment for age at baseline and race, IMT increased substantially in the late perimenopausal stage (0.017 mm/y) compared with the premenopausal stage (0.007 mm/y) and the early perimenopausal stage (0.005 mm/y; P G 0.05 for both comparisons; Fig. 1A ). For AD, although the overall rate of change was negative (j0.009 mm/y), the direction of the change rate varied by menopausal stage. The annual rate of change was negative during the premenopausal and early perimenopausal stages, and this switched to a positive change at the late perimenopausal and postmenopausal stages. For these later periods, increases in AD were remarkable (0.024 mm/y in the late perimenopausal stage and 0.018 mm/y in the postmenopausal stage) and significantly different from the rate of change in the premenopausal stage (j0.032 mm/y; P G 0.05 for both comparisons; Fig. 1B) . The primary factors that were found to be significantly associated with greater IMT were older age, BMI, waist circumference, diastolic blood pressure, systolic blood pressure (SBP), LDL-c, triglycerides, glucose, insulin, HOMA index, and CRP. With the exception of age, LDL-c, and CRP, all previously mentioned factors, in addition to lower highdensity lipoprotein cholesterol, were found to be significantly associated with a larger AD. A larger AD was found to be significantly associated with greater IMT (P G 0.0001). Of these factors, higher SBP and BMI were independently associated with greater IMT and AD (P e 0.05) after adjustment for baseline age, time since baseline, race, and comorbidity (data not shown). Tables 3 and 4 show the effects of menopause status on IMT and AD levels, respectively. Being postmenopausal was independently associated with larger levels of IMT and AD compared with being premenopausal in models adjusted for risk factors (model 2 in Tables 3 and 4 ). No significant differences were found in IMT or AD levels between postmenopause status and late perimenopause status (P Q 0.05).
Because IMT and AD are significantly related to each other, we evaluated the independent effect of menopause status on each measure while adjusting for the other. For IMT level, adjusting for AD at baseline significantly attenuated the independent effect of menopause status. Conversely, adjusting for IMT at baseline did not significantly affect the independent effect of menopause status on AD level.
DISCUSSION
In the current longitudinal study, the progression rates of IMT and AD differed by the menopausal transition stage. This structural remodeling of the carotid artery was most evident during the late perimenopausal stage in comparison with the premenopausal and early perimenopausal stages. The thickness of the carotid intima-media layer substantially increased during the late perimenopausal stage compared with the pre-menopausal and early perimenopausal stages. Moreover, the AD of the carotid artery decreased during the premenopausal and early perimenopausal stages and noticeably increased in both the late perimenopausal stage and the postmenopausal stage compared with the premenopausal stage.
Multivariable analyses showed that larger baseline IMT, postmenopause status, higher BMI, and SBP were independently associated with a larger AD, whereas a larger baseline AD and higher BMI were found to be independently related to larger IMT.
The current longitudinal study demonstrates for the first time that the progression rates of IMT and AD substantially increase at the late perimenopause stage, irrespective of age at baseline and ethnicity. These data highlight late perimenopause as a stage of vascular remodeling during which arteries become more vulnerable. Late perimenopause is also the stage during which women are subjected to several physiological and hormonal changes that, in combination with vessel remodeling, may place older women at higher risk for developing atherosclerosis.
Our current finding for AD is in line with previous crosssectional analyses among SWAN Heart participants, demonstrating that late perimenopause and postmenopause are associated with a larger AD. 12 Although the cross-sectional analyses failed to document similar findings for IMT, our longitudinal analyses, which are more powerful, have reported thicker IMT in postmenopausal women and greater IMT progression in the late perimenopausal stage compared with the premenopausal and early perimenopausal stages. In a European study of 74 early postmenopausal women and 74 nonpostmenopausal women comparable for age and BMI, a larger common carotid luminal diameter and greater IMT were observed in the early postmenopausal group compared with the nonpostmenopausal group. 22 Using longitudinal data from the Los Angeles Atherosclerosis Study, Johnson et al 23 reported that women transitioning from premenopause to postmenopause within a 3-year period had a higher rate of 
Intercept
Average of AD at baseline scan, mm 6.706 (0.038) G0.001 6.971 (0.075) G0.001 6.859 (0.072) G0.001 6.800 (0.072) G0.001 Slope Average annual rate of change in AD, mm/y j0.009 (0.004) 0.02 j0.022 (0.006) 0.0003 j0.024 (0.006) G0.001 j0.023 (0.006) G0.001 IMT progression compared with women with a slower menopausal transition. These results suggest an accelerated progression of IMT during the perimenopausal stage. Our results confirm these findings and extend them to a longitudinal setting. Figure 1A shows that the progression rate of IMT during the postmenopausal stage seems to be less than that reported during the late perimenopausal stage. However, this difference was not statistically significant. It was expected that there would be a similar or even greater level of IMT progression in the postmenopausal stage compared with the late perimenopausal stage. A plausible explanation for this unexpected result is probably related to the limited follow-up time contributed by the postmenopausal women compared with that contributed by the late perimenopausal women in the current study. For 90% of the observations, the time spent in the late perimenopausal stage during the follow-up period was 0.92 years or less, whereas that spent in the postmenopausal stage was 0.39 years or less. Currently, on SWAN visit 12, we are collecting an additional time point for IMT that will be very valuable in evaluating whether the change in IMT during the postmenopausal stage would be similar to or greater than that reported during the late perimenopausal stage.
It may be surprising that the overall progression rate of AD decreased over time in the early stages of menopause. The literature has reported inconsistent associations (positive or null) between AD and age. 24, 25 None of the previous studies focused on women or assessed the impact of menopause status on age-diameter association. Our results indicate the likely reason for these inconsistent findings. Although the data show a reduction in AD overall, the progression rates differ significantly by menopausal stage. AD decreased only when women were premenopausal or early perimenopausal. When women reached late perimenopause, the change in AD became positive. This pattern may be explained by concurrent changes in hormones, primarily in estradiol (E 2 ). Crosssectional data from SWAN Heart revealed that lower levels of E 2 were associated with a larger AD after adjustment for traditional cardiovascular risk factors. 12 Thus, if E 2 levels influence AD over the course of the transition, then higher levels of E 2 in the premenopausal and early perimenopausal stages would be associated with a smaller AD. It is important to remember that the trajectory of E 2 does not uniformly decrease across the menopausal transition. It has been observed that E 2 may increase toward the final menstrual period before it consistently decreases. 26 Several mechanisms can be postulated to explain the observed significant effect of menopause status on subclinical measures and CVDs. Transitioning through menopause is accompanied by many physiological changes that place women at higher risk for the development of CVDs. These changes are most probably attributed to alterations in sex hormones during the menopausal transition. Both low sex hormoneY binding globulin level and high free testosterone level were found to be strongly associated with a worse CVD risk profile among premenopausal and perimenopausal women from SWAN. 14 The increase in body weight and the alteration in body fat distribution are changes related to the menopausal transition. 27 In addition, alteration in the lipid profile occurs with the menopausal transition and is related to sex hormone levels. 14 Previous data from SWAN showed that lipids increased exponentially around the final menstrual periodVas compared with either before or afterVamong all ethnic groups. 28 IMT is a well-established index for atherosclerosis that has been associated with an unfavorable cardiovascular risk profile. 29 Although the subject of fewer publications, AD has also been shown to be an informative measure of vascular remodeling among women. A larger AD is correlated with adverse cardiovascular risk factors 30 and is associated with a higher risk of coronary heart disease. 31 A dilated artery may itself lead to a disturbance in blood flow, as a wider artery may have less ability to dilate further in response to stimulus, which may make the artery more vulnerable to damage.
We found that current SBP and BMI were significantly associated with larger IMT and AD in the final models. In addition, postmenopausal women had significantly larger IMT and AD compared with premenopausal women. Adjusting for baseline IMT did not change the independent effect of menopause status on AD in the current study; however, adjusting for baseline AD attenuated the independent effect of menopause status on IMT. These findings suggest that arterial dilation may occur first in response to lower E 2 levels. 12 Wall thickening would then follow as a mechanism to normalize levels of tensile stress that would be increased when the artery dilates. 22 These findings may explain the different levels of progression rates in IMT and AD observed in the postmenopausal stage, as denoted in Fig. 1A and B . Because we did not have enough follow-up time in the postmenopausal stage, it is most likely that we were not able to detect significant wall thickening in response to the significant AD dilatation.
The current study has some limitations. Approximately 40% of the study population was followed for a maximum of 2.5 years. The preponderance of premenopausal and early perimenopausal women who did not transition to postmenopause during the study means that our overall results are weighted toward the early stages of the transition. Additional data from later periods during the menopausal transition, including early postmenopause, will be valuable. However, the statistical analysis method that we used proved appropriate for handling this problem, as it focused on the time spent at each stage rather than on how many women transitioned to a certain stage. We estimated the progression rate for each stage of the menopausal transition. Second, the sample size limited our ability to adjust for more covariates when comparing the progression rates between stages. However, this should not bias the results, as our findings were consistent with previous cross-sectional findings that adjusted for most of the traditional risk factors. 12 This study is the first to estimate the progression rates of IMT and AD at each stage of the menopausal transition in a population of women at midlife. The next step in this line of research would be to determine the exact role of endogenous sex hormones in the progression rates of IMT and AD in women transitioning through menopause. Examination of reproductive hormones, in association with vascular adaptation, would shed light on the possible mechanisms for the significant vascular remodeling that we have observed starting at the late perimenopausal stage of the menopausal transition.
CONCLUSIONS
Our data suggest that, during the menopausal transition and particularly during late perimenopause, the carotid artery may undergo adaptation, which is reflected as increases in AD followed by increases in IMT. These changes may have an impact on the vulnerability of the vessel in the postmenopausal period. The current study highlights late perimenopause as a time point when early intervention strategies targeting CVDs might yield the greatest benefit.
